OBJECTIVE: To systematically evaluate the clinical efficacy and safety of Shufeng Jiedu capsules in the adjuvant treatment of acute upper respiratory tract infection（ AURTI）. METHODS: CNKI

VIP database

Wanfang database

CBM

PubMed

the Cochrane Library

Embase and Web of Science were retrieved to collect the randomized controlled trial of Shufeng Jiedu capsules in the adjuvant treatment of AURTI（ the study group was treated with Shufeng Jiedu capsules combined with conventional Western medicine

while the control group received conventional Western medicine）. The retrieval time was from the establishment of the database to Apr. 24 th

2021.The Cochrane Collaboration risk of bias tool was used for risk assessment and quality evaluation of the included literature

and Stata 15. 0 software was used for Meta-analysis. RESULTS: Totally 11 randomized controlled trials were collected

including 1 481 patients. Meta-analysis showed that the total effective rate in the study group was significantly better than that in the control group（ RR = 1. 14

95% CI = 1. 10-1. 19

P < 0. 01）

and in the subgroup analysis

the total effective rate of adult patients（ RR = 1. 16

95%CI = 1. 10-1. 24

P<0. 01） and children（ RR = 1. 13

95% CI = 1. 08-1. 18

P < 0. 01） in the study group were significantly better than those in the control group

the differences were statistically significant. The duration of fever（ WMD =-1. 37

95% CI =-1. 70--1. 05

P < 0. 01）

disappearance time of cough（ WMD =-1. 21

95% CI =-1. 40--1. 02

P < 0. 01） and pharyngeal swelling（ WMD =-1. 39

95%CI =-1. 93--0. 85

P<0. 01） in the study group were significantly shorter than those in the control group

and the differences were statistically significant. There was statistically significant difference in the incidence of adverse drug reactions between two groups（ RR = 0. 32

95% CI = 0. 14-0. 73

P = 0. 007）. In subgroup analysis

there was no statistically significant difference in the incidence of adverse drug reactions between two groups of adult patients（ RR =0. 40

95%CI = 0. 08-2. 02

P = 0. 268）. There was statistically significant difference in the incidence of adverse drug reactions between two groups of children（ RR = 0. 30

95%CI = 0. 11-0. 78

P = 0. 014）. CONCLUSIONS: The efficacy of Shufeng Jiedu capsules in the adjuvant treatment of AURTI is better than that of Western medicine alone

which can improve the clinical symptoms of patients with few adverse drug reactions. However

due to the limitations of included literature

the above conclusions still need to be verified by the rigorously designed randomized controlled study with larger sample size.